Single-Hormone Artificial Pancreas Use in Diabetes: Clinical Efficacy and Remaining Challenges

Nadine Taleb; Sémah Tagougui; Rémi Rabasa-Lhoret

doi:10.2337/ds18-0094

Single-Hormone Artificial Pancreas Use in Diabetes: Clinical Efficacy and Remaining Challenges

Diabetes Spectr. 2019 Aug;32(3):205-208. doi: 10.2337/ds18-0094.

Authors

Nadine Taleb^{1

2}, Sémah Tagougui^{1

3}, Rémi Rabasa-Lhoret^{1

3

4}

Affiliations

¹ Clinical Research Institute, Montreal, Quebec, Canada.
² Department of Biomedical Sciences, Université de Montréal, Montreal, Quebec, Canada.
³ Department of Nutrition, Université de Montréal, Montreal, Quebec, Canada.
⁴ Montreal Diabetes Research Center & Endocrinology Division Montreal, Quebec, Canada.

Abstract

IN BRIEF Artificial pancreas systems are rapidly developing and constitute the most promising technology for insulin-requiring diabetes management. Single-hormone systems (SH-AP) that deliver only insulin and have a hybrid design that necessitates patients' interventions around meals and exercise are the first to appear on the market. Trials with SH-AP have demonstrated improvement in time spent with blood glucose levels within target ranges, with a concomitant decrease in hypoglycemia. Longer and larger trials involving different patient populations are ongoing to further advance this important technology.